Strategic Medicine

Strategic Medicine, Inc. (SMI) was a biotechnology company dedicated to the advancement of personalized medicine through the discovery and application of molecular biomarkers. The company utilized a proprietary molecular profiling platform to identify genetic and protein signatures that could predict disease progression and therapeutic response, with a primary focus on oncology and breast cancer. SMI worked in close collaboration with the Windber Research Institute to translate large-scale genomic and proteomic data into clinical tools for patient stratification and trial optimization. Its business model centered on providing diagnostic insights and molecular imaging solutions to improve the precision of clinical development and patient care.